Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 13 results.
User Information
Export Records
  1. 1.   A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
  2. Manzo, Julia; Puhalla, Shannon; Pahuja, Shalu; Ding, Fei; Lin, Yan; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Diergaarde, Brenda; Kiesel, Brian F; Yu, Jing; Tan, Antoinette R; Belani, Chandra P; Chew, Helen; Garcia, Agustin A; Morgan, Robert J; Wahner Hendrickson, Andrea E; Visscher, Daniel W; Hurley, Rachel M; Kaufmann, Scott H; Swisher, Elizabeth M; Oesterreich, Steffi; Katz, Tiffany; Ji,Jay; Zhang, Yiping; Parchment, Ralph E; Chen, Alice; Duan, Wenrui; Giranda, Vincent; Shepherd, Stacie P; Ivy, S Percy; Chu, Edward; Beumer, Jan H
  3. Cancer Chemotherapy and Pharmacology. 2022, Apr 18; 89(5): 721-735.
  1. 2.   Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
  2. Kummar, Shivaani; Srivastava,Apurva; Navas, Tony; Cecchi, Fabiola; Lee, Young H.; Bottaro, Donald P.; Park, Sook Ryun; Do, Khanh T.; Jeong, Woondong; Johnson, Barry C.; Voth, Andrea R.; Rubinstein, Larry; Wright, John J.; Parchment,Ralph; Doroshow, James H.; Chen, Alice P.
  3. Investigational new drugs. 2021, Jun 28;
  1. 3.   Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
  2. Coyne, Geraldine O'Sullivan; Kummar, Shivaani; Meehan, Robert S; Do, Khanh; Collins, Jerry M; Anderson, Larry; Ishii, Kazusa; Takebe, Naoko; Zlott, Jennifer; Juwara,Lamin; Piekarz, Richard; Streicher, Howard; Sharon, Elad; Rubinstein, Larry; Voth,Andrea; Lozier, Jay; Dull,Angie; Wilsker,Deborah; Hinoue, Toshinori; Laird, Peter W; Ferry-Galow,Katherine; Kinders,Robert; Parchment,Ralph; Doroshow,Jim; Chen, Alice P
  3. Oncotarget. 2020, Nov 03; 11(44): 3959-3971.
  1. 4.   Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase 2b Trial
  2. Lee, Sulggi A; Elliott, Julian H; McMahon, James; Hartogenesis, Wendy; Bumpus, Namandje N; Lifson, Jeffrey; Gorelick, Robert; Bacchetti, Peter; Deeks, Steven G; Lewin, Sharon R; Savic, Radojka M
  3. Clinical pharmacology and therapeutics. 2019, Mar; 105(3): 692-702.
  1. 5.   Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras(G12D/+);Tp53(R172H/+) (KPC) mice, a genetically engineered model of pancreatic cancer
  2. Vilimas, Tomas; Wang, Amy Q.; Patnaik, Samarjit; Hughes, Emma A.; Singleton, Marc D.; Knotts, Zachary; Li, Dandan; Frankowski, Kevin; Schlomer, Jerome; Guerin, Theresa; Springer, Stephanie; Drennan, Catherine; Dextras, Christopher; Wang, Chen; Gilbert, Debra; Southall, Noel; Ferrer, Marc; Huang, Sui; Kozlov, Serguei; Marugan, Juan; Xu, Xin; Rudloff, Udo
  3. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2018, Dec; 82(6): 1067-1080.
  1. 6.   Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran
  2. Kumar, Parag; Gordon, Lori A.; Brooks, Kristina M.; George, Jomy M.; Kellogg, Anela; McManus, Maryellen; Alfaro, Raul M.; Nghiem, Khanh; Lozier, Jay; Hadigan, Colleen; Penzak, Scott R.
  3. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017, NOV; 61(11):
  1. 7.   Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.
  2. Gordon, Lori A; Kumar, Parag; Brooks, Kristina M; Kellogg, Anela; McManus, Maryellen; Alfaro, Raul M; Nghiem, Khanh; George, Jomy M; Lozier, Jay; Penzak, Scott R; Hadigan, Colleen
  3. Circulation. 2016, Dec 6; 134(23): 1909-1911.
  1. 8.   Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials
  2. Kummar, S.; Do, K.; Coyne, G. O.; Chen, A.; Ji, J.; Rubinstein, L.; Doroshow, J. H.
  3. Seminars in Oncology. 2016, Aug; 43(4): 446-52.
  1. 9.   Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells
  2. Wang, L.; Balasubramanian, P.; Chen, A. P.; Kummar, S.; Evrard, Y. A.; Kinders, R. J.
  3. Seminars in Oncology. 2016, Aug; 43(4): 464-75.
  1. 10.   Phase 0 clinical trials: Conceptions and misconceptions
  2. Kummar, S.; Rubinstein, L.; Kinders, R.; Parchment, R. E.; Gutierrez, M. E.; Murgo, A. J.; Ji, J.; Mroczkowski, B.; Pickeral, O. K.; Simpson, M.; Hollingshead, M.; Yang, S. X.; Helman, L.; Wiltrout, R.; Collins, J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Journal. 2008 14(3): 133-137.
  1. 11.   Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: Implications for antifungal therapy
  2. Hope, W. W.; Kruhlak, M. J.; Lyman, C. A.; Petraitiene, R.; Petraitis, V.; Francesconi, A.; Kasai, M.; Mickiene, D.; Sein, T.; Peter, J.; Kelaher, A. M.; Hughes, J. E.; Cotton, M. P.; Cotten, C. J.; Bacher, J.; Tripathi, S.; Bermudez, L.; Maugel, T. K.; Zerfas, P. M.; Wingard, J. R.; Drusano, G. L.; Walsh, T. J.
  3. Journal of Infectious Diseases. 2007, Feb; 195(3): 455-466.
  1. 12.   Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort
  2. Robertson, S. M.; Formentini, E.; Alfaro, R. M.; Natarajan, V.; Falloon, J.; Penzak, S. R.
  3. British Journal of Clinical Pharmacology. 2006, Apr; 61(4): 379-388.
  1. 13.   Novel Superiority Tests for Anti-Infective Drug Trials: Three Examples
  2. Brittain, Erica; Follmann, Dean; Joshi, Gyan
  3. Statistics in Biopharmaceutical Research. 2018 10(1): 9-17.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel